Northwestern Mutual Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-598	Closed	-$8.05K	–	3602
2023 Q4	$8.05K	Buy	+598	New	+$6.53K	﹤0.01%	2714
2023 Q1	–	Sell	-10	Closed	-$137	–	3390
2022 Q4	$137	Hold	10	–	–	﹤0.01%	3208
2022 Q3	$0	Hold	10	–	–	﹤0.01%	3157
2022 Q2	$0	Hold	10	–	–	﹤0.01%	3215
2022 Q1	$0	Hold	10	–	–	﹤0.01%	3142
2021 Q4	$0	Buy	+10	New	+$278	﹤0.01%	3161
2019 Q4	–	Sell	-40	Closed	-$1K	–	2415
2019 Q3	$1K	Buy	+40	New	+$812	﹤0.01%	2333

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Northwestern Mutual Wealth Management's CNCR Position: Q1 2024 in Review

Northwestern Mutual Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2024, closing a stake of 598 shares — an estimated $8.05K sold.

Northwestern Mutual Wealth Management first reported a position in CNCR in Q3 2019 and held it in 7 quarters. The position peaked at $8.05K in Q4 2023. 16 funds tracked by Wall St. Rank hold CNCR as of Q1 2024.

Northwestern Mutual Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2024 after selling out during the quarter.
Northwestern Mutual Wealth Management sold 598 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2024, an estimated $8.05K.
Northwestern Mutual Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2019 and held it in 7 quarters.
Northwestern Mutual Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $8.05K in Q4 2023.
16 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2024.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.